Objective To explore the symptomatic improvement and adverse effects of oseltamivir in the treatment of children with influenza A or B.Methods The clinical data of 81 children with influenza admitted to Sun Yat-sen Memorial Hospital,Sun Yat-sen University from June 2020 to September 2022 were retrospectively analyzed.The 81 children were classified into influenza A group(n=47)and influenza B group(n=34)according to antigen detection results.All children were treated with oseltamivir phosphate,then the symptom improvement time,clinical efficacy and occurrence of adverse reactions were compared between the 2 groups.Results The time to improvement of high fever,cough,nasal congestion and runny nose,and systemic symptoms was(1.62±0.53)d,(3.20±0.75)d,(4.08±1.24)d,and(4.10±1.26)d respectively in influenza A group,which were all shorter than those of influenza B group((3.47±0.78)d,(4.61±1.35)d,(5.11±1.27)d,and(5.56±1.50)d),showing statistical difference(all P<0.05).The clinical efficacy rate in influenza A group(95.74%,45/47)was higher than that in the influenza B group(82.35%,28/34)(P<0.05).There was no statistically significant difference in adverse reaction rate between the two groups(10.63%(5/47),11.67%(4/34),P>0.05).Conclusion Oseltamivir is effective in treating both influenza A and B in children with fewer adverse effects.And it is more effective in treating children with influenza A than the those with influenza B in terms of clinical symptom improvement.
NETL
NSTL
万方数据
